- SYNTHESIS OF INDOLES FROM ACETOACETIC ESTERS
-
The present invention relates to a synthesizing method of indole using acetoacetic ester and, more specifically, to a synthesizing method of indole which induces reduction of a nitro group into an amine group and aromatic cyclization with a ketone group through hydrogenation using a metal catalyst in a 2-nitrobenzyl ketone compound, after synthesizing the 2-nitrobenzyl ketone compound through deacetylation using a manganese (III) / cobalt (II) catalyst in a 2-nitrobenzyl acetone compound obtained by adding an acetoacetic ester compound in a 2-nitrobenzyl bromide compound.COPYRIGHT KIPO 2016
- -
-
-
- Tandem catalytic oxidative deacetylation of acetoacetic esters and heteroaromatic cyclizations
-
One pot syntheses of furan, thiophene, and pyrrole were accomplished by oxidative deacetylation using Mn(iii)/Co(ii) catalysts and the Paal-Knorr reaction from 1,5-dicarbonyl compounds, which are prepared from the conjugate addition of ethyl acetoacetate to α,β-unsaturated carbonyl compounds. The oxidative deacetylation and reductive cyclization of β-ketoesters derived from ethyl acetoacetate and o-nitrobenzyl bromides efficiently produced diversely substituted indoles. This journal is
- Ju, Yeming,Miao, Di,Yu, Ruiyang,Koo, Sangho
-
p. 2588 - 2599
(2015/04/21)
-
- MK2 INHIBITORS AND USES THEREOF
-
The present invention provides compounds, compositions thereof, and methods of using the same.
- -
-
Paragraph 00802; 00826
(2014/10/03)
-
- HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE
-
Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.
- -
-
Page/Page column 40-41
(2011/06/26)
-
- Pyrazinoindolone inhibitors of MAPKAP-K2
-
Optimization of pyrazinoindolone inhibitors of MAPKAP-K2 (MK2) provides a reasonable balance of cellular potency and physicochemical properties. Mechanistic studies support the inhibition of MK2 which is responsible for the sub-micromolar cellular efficacy.
- Goldberg,Choi,Cogan,Corson,DeLeon,Gao,Gruenbaum,Hao,Joseph,Kashem,Miller,Moss,Netherton,Pargellis,Pelletier,Sellati,Skow,Torcellini,Tseng,Wang,Wasti,Werneburg,Wu,Xiong
-
p. 938 - 941
(2008/09/21)
-
- Anti-Cytokine Heterocyclic Compounds
-
Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.
- -
-
Page/Page column 32-33
(2010/11/25)
-